Regeneron Wins CHMP Backing of Lymphoma Drug Odronextamab
By Colin Kellaher
Regeneron Pharmaceuticals on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of odronextamab for certain patients with the two most-common subtypes of non-Hodgkin lymphoma.
The Tarrytown, N.Y., biotechnology company said the recommendation covers odronextamab for adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic therapy.
The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected in the coming months.
The U.S. Food and Drug Administration in March turned away Regeneron's application seeking approval of odronextamab due to issues related to the enrollment status of confirmatory trials.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 28, 2024 07:44 ET (11:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks